1. Home
  2. FFIV vs VTRS Comparison

FFIV vs VTRS Comparison

Compare FFIV & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo F5 Inc.

FFIV

F5 Inc.

HOLD

Current Price

$290.22

Market Cap

14.9B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$13.47

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FFIV
VTRS
Founded
1996
1961
Country
United States
United States
Employees
N/A
30000
Industry
Computer Communications Equipment
Medicinal Chemicals and Botanical Products
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.9B
17.2B
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
FFIV
VTRS
Price
$290.22
$13.47
Analyst Decision
Hold
Buy
Analyst Count
10
4
Target Price
$305.50
$13.50
AVG Volume (30 Days)
615.9K
7.8M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
3.53%
EPS Growth
23.56
N/A
EPS
3.10
N/A
Revenue
$3,088,072,000.00
$14,299,900,000.00
Revenue This Year
$8.00
$4.41
Revenue Next Year
$3.27
$1.96
P/E Ratio
$95.05
N/A
Revenue Growth
9.66
N/A
52 Week Low
$223.76
$7.34
52 Week High
$346.00
$16.47

Technical Indicators

Market Signals
Indicator
FFIV
VTRS
Relative Strength Index (RSI) 49.50 45.81
Support Level $283.21 $12.90
Resistance Level $304.54 $13.63
Average True Range (ATR) 9.93 0.30
MACD -0.08 0.06
Stochastic Oscillator 33.36 65.03

Price Performance

Historical Comparison
FFIV
VTRS

About FFIV F5 Inc.

F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: